You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
Update on tominersen clinical trials
GENERATION HD1 (NCT03761849) was a randomised, multicentre, double-blind, Phase III, placebo-controlled trial designed to evaluate the safety and efficacy of tominersen in adults with manifest Huntington’s disease. In March 2021, dosing was stopped in GENERATION HD1 following a recommendation from the independent data monitoring committee. Post hoc analyses from GENERATION HD1 suggested that tominersen at lower exposures may have potential benefit in younger adult individuals with less disease burden. This hypothesis will be investigated in the new Phase II study of tominersen, GENERATION HD2.
Request medical material
Would you like to receive this poster via email to view later?